Amyloid-Journal of Protein Folding Disorders

Papers
(The TQCC of Amyloid-Journal of Protein Folding Disorders is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Therapeutic effect of TTR siRNA on hereditary transthyretin amyloidosis (ATTRv) nephropathy215
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres190
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies92
Changes in the amyloid editorial board members and in editor positions76
A second case of liraglutide-type localised amyloidosis59
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain40
The way to a man’s heart: prostate samples for the early detection of transthyretin cardiomyopathy34
Iatrogenic cerebral amyloid angiopathy rather than sporadic CAA in younger adults with lobar intracerebral haemorrhage28
Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial26
Oxidative conversion of transthyretin in formalin-fixed clinical amyloid samples results in the formation of the His90Asp and His90Asn variants20
In memoriam: Lawreen Connors, Ph.D.19
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage19
Post-translational modification of amyloid a protein in patients with AA amyloidosis17
Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis17
Refining prognostication in systemic AL amyloidosis: limited value of dFLC14
Utilization and tolerance of beta-blockers among patients with AL amyloidosis14
Brain MRI in patients with V30M hereditary transthyretin amyloidosis14
A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis14
An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis13
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration13
Metabolomics analysis for diagnosis and biomarker discovery of transthyretin amyloidosis13
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China12
Pupillometric findings in ATTRv patients and carriers: results from a single-centre experience12
High frequency of occult transthyretin and apolipoprotein AI–type amyloid in aortic valves removed by valve replacement for aortic stenosis12
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis11
Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis11
Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis10
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures10
A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosis9
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays9
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee9
Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation8
Monitoring of cardiac transthyretin amyloid load by [99mTc]DPD scintigraphy: is it the end of the semi-quantitative evaluation?8
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation8
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis8
Gastrointestinal Amyloid Screening Study (GASS): is screening for amyloid in the gastrointestinal tract useful?7
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study7
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis7
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?7
Symptomatic SARS-CoV2 infection associated with high mortality in AA amyloidosis7
A novel approach for evaluating transthyretin kinetic stabilizers using plasma samples7
A novel APOA1 frameshift mutation Glu120Glyfs*60 with upper gastrointestinal involvement and an indolent course7
Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis7
Amyloidosis from the patient perspective: the French daily impact of amyloidosis study6
Characterization of population genetic structure of hereditary transthyretin amyloidosis in Bulgaria6
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis6
T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy6
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey6
The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expression5
Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosis5
Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA)5
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial5
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases5
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study5
AA amyloidosis in vertebrates: epidemiology, pathology and molecular aspects5
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study5
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee5
Fibrinogen A α-chain amyloidosis associated with a rare frameshift pathogenic variant p.Arg547GlyfsTer215
Clinical and genetic features of AGel amyloidosis caused by novel gelsolin variant and its impact on cardiac function and conduction disorders5
0.25588393211365